Why the Patent Battle over CRISPR Matters (and Why It Doesn’t)

January 10, 2017

(Gizmodo) – By the time a panel of judges at the U.S. Patent and Trademark Office gets around to deciding who owns the biggest biotechnology innovation of the century, CRISPR-Cas9 may have already lost its heavyweight title as the most precise tool for genetic engineering. In the bitter patent battle between the Broad Institute and U.C. Berkeley that reached a courtroom climax last month, both institutions are duking it out for the right to claim that they invented CRISPR-Cas9, along with the right to reap millions and millions of dollars for licensing their discovery.

Recommended Reading